Dogwood Therapeutics (DWTX) SVP awarded 82,500-share stock option grant

Rhea-AI Filing Summary

Grosswald Ralph reported acquisition or exercise transactions in this Form 4 filing.

Dogwood Therapeutics, Inc. reported that SVP of Operations Ralph Grosswald received a grant of stock options covering 82,500 shares of the company’s stock. These options were awarded as a form of equity compensation.

According to the disclosure, the option vests one-third on March 5, 2027, with the remaining portion vesting in equal 1/24th monthly installments thereafter, tying most of the award to continued service over time.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grosswald Ralph

(Last) (First) (Middle)

C/O DOGWOOD THERAPEUTICS, INC.

44 MILTON AVENUE

(Street)

ALPHARETTA GA 30009

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dogwood Therapeutics, Inc. [ DWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP OF OPERATIONS

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.86	03/05/2026		A		82,500		(1)	03/05/2036	Common Stock	82,500	$0	82,500	D

Explanation of Responses:

1. The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter.

	/s/ Greg Duncan, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Dogwood Therapeutics (DWTX) report for Ralph Grosswald?

Dogwood Therapeutics reported that SVP of Operations Ralph Grosswald was granted stock options for 82,500 shares. The award is classified as a derivative security and represents an equity-based compensation grant rather than an open-market purchase or sale of common stock.

Is the Dogwood Therapeutics (DWTX) Form 4 transaction a buy or a sale?

The Form 4 transaction is an acquisition by grant, not a market buy or sale. Ralph Grosswald received a stock option award for 82,500 shares as compensation, classified under code “A” for grant, award, or other acquisition of derivative securities.

How many stock options did Dogwood Therapeutics (DWTX) grant to its SVP of Operations?

Dogwood Therapeutics granted its SVP of Operations, Ralph Grosswald, a stock option covering 82,500 shares. Following this grant, the total options reported owned from this award are 82,500, all held as direct beneficial ownership according to the Form 4 filing.

What is the vesting schedule for Ralph Grosswald’s Dogwood Therapeutics (DWTX) stock options?

The stock option vests one-third on March 5, 2027, with the remaining two-thirds vesting in 1/24th monthly installments thereafter. This schedule spreads the vesting over multiple years, encouraging ongoing service and alignment with the company’s long-term performance.

What does transaction code “A” mean in the Dogwood Therapeutics (DWTX) Form 4?

Transaction code “A” on the Form 4 indicates a grant, award, or other acquisition of a security, rather than a market purchase. In this case, it reflects the stock option award of 82,500 derivative securities to SVP of Operations Ralph Grosswald.

Is Ralph Grosswald’s ownership in Dogwood Therapeutics (DWTX) direct or indirect after this option grant?

The Form 4 indicates that Ralph Grosswald’s ownership from this stock option grant is direct. The filing labels the ownership type and code as direct, and there are no footnotes reallocating this award to a separate entity or trust.